135 related articles for article (PubMed ID: 12880279)
61. Azidothymidine inhibits cell growth and telomerase activity and induces DNA damage in human esophageal cancer.
Wang H; Zhou J; He Q; Dong Y; Liu Y
Mol Med Rep; 2017 Jun; 15(6):4055-4060. PubMed ID: 28487971
[TBL] [Abstract][Full Text] [Related]
62. 3'-Azido-3'-deoxythymidine (AZT) and AZT-resistant reverse transcriptase can increase the in vivo mutation rate of human immunodeficiency virus type 1.
Mansky LM; Bernard LC
J Virol; 2000 Oct; 74(20):9532-9. PubMed ID: 11000223
[TBL] [Abstract][Full Text] [Related]
63. Catabolism of 3'-azido-3'-deoxythymidine in hepatocytes and liver microsomes, with evidence of formation of 3'-amino-3'-deoxythymidine, a highly toxic catabolite for human bone marrow cells.
Cretton EM; Xie MY; Bevan RJ; Goudgaon NM; Schinazi RF; Sommadossi JP
Mol Pharmacol; 1991 Feb; 39(2):258-66. PubMed ID: 1996084
[TBL] [Abstract][Full Text] [Related]
64. Effect of short-term exposure to zidovudine (AZT) on the expression of mitochondria-related genes in skeletal muscle of neonatal mice.
Desai VG; Lee T; Moland CL; Branham WS; Von Tungeln LS; Beland FA; Fuscoe JC
Mitochondrion; 2009 Feb; 9(1):9-16. PubMed ID: 18824140
[TBL] [Abstract][Full Text] [Related]
65. Interaction of 3'-azido-3'-deoxythymidine with organic ion transport in rat renal basolateral membrane vesicles.
Griffiths DA; Hall SD; Sokol PP
J Pharmacol Exp Ther; 1991 Apr; 257(1):149-55. PubMed ID: 1826925
[TBL] [Abstract][Full Text] [Related]
66. Human recombinant interferon alpha-2a plus 3'-azido-3'-deoxythymidine. Synergistic growth inhibition with evidence of impaired DNA repair in human colon adenocarcinoma cells.
Darnowski JW; Davol PA; Goulette FA
Biochem Pharmacol; 1997 Feb; 53(4):571-80. PubMed ID: 9105409
[TBL] [Abstract][Full Text] [Related]
67. ATP binding cassette multidrug transporters limit the anti-HIV activity of zidovudine and indinavir in infected human macrophages.
Jorajuria S; Dereuddre-Bosquet N; Becher F; Martin S; Porcheray F; Garrigues A; Mabondzo A; Benech H; Grassi J; Orlowski S; Dormont D; Clayette P
Antivir Ther; 2004 Aug; 9(4):519-28. PubMed ID: 15456083
[TBL] [Abstract][Full Text] [Related]
68. The effect of recombinant human granulocyte-macrophage colony-stimulating factor (rGM-CSF) on 3'-azido-3'-deoxythymidine (AZT)-mediated biochemical and cytotoxic effects on normal human myeloid progenitor cells.
Bhalla K; Birkhofer M; Grant S; Graham G
Exp Hematol; 1989 Jan; 17(1):17-20. PubMed ID: 2783247
[TBL] [Abstract][Full Text] [Related]
69. AZT on telomerase activity and cell proliferation in HS 839.T melanoma cells.
Souza Sobrinho CP; Gragnani A; Santos ID; Oliveira AF; Lipay MV; Ferreira LM
Acta Cir Bras; 2012 Dec; 27(12):855-60. PubMed ID: 23207751
[TBL] [Abstract][Full Text] [Related]
70. Paclitaxel and Sorafenib: The Effective Combination of Suppressing the Self-Renewal of Cancer Stem Cells.
Nawara HM; M Afify S; Hassan G; Zahra MH; Atallah MN; Mansour H; Abu Quora HA; Alam MJ; Osman A; Kakuta H; Hamada H; Seno A; Seno M
Cancers (Basel); 2020 May; 12(6):. PubMed ID: 32466563
[TBL] [Abstract][Full Text] [Related]
71. Effect of 3`-Azido-3`-Deoxythymidine (AZT) on Telomerase Activity and Proliferation of HO-8910 Cell Line of Ovarian Cancer.
Dinman JD
Int J Biomed Sci; 2006 Feb; 2(1):41. PubMed ID: 23674965
[No Abstract] [Full Text] [Related]
72. Statistical Assessment of Drug Synergy from In Vivo Combination Studies Using Mouse Tumor Models.
Mao B; Guo S
Cancer Res Commun; 2023 Oct; 3(10):2146-2157. PubMed ID: 37830749
[TBL] [Abstract][Full Text] [Related]
73. Drug synergy scoring using minimal dose response matrices.
Mäkelä P; Zhang SM; Rudd SG
BMC Res Notes; 2021 Jan; 14(1):27. PubMed ID: 33468238
[TBL] [Abstract][Full Text] [Related]
74. Investigation of the robustness of two models for assessing synergy in pre-clinical drug combination studies.
Whitehead A; Su TL; Thygesen H; Sperrin M; Harbron C
Pharm Stat; 2013; 12(5):300-8. PubMed ID: 23907796
[TBL] [Abstract][Full Text] [Related]
75. Synergistic drug combinations tend to improve therapeutically relevant selectivity.
Lehár J; Krueger AS; Avery W; Heilbut AM; Johansen LM; Price ER; Rickles RJ; Short GF; Staunton JE; Jin X; Lee MS; Zimmermann GR; Borisy AA
Nat Biotechnol; 2009 Jul; 27(7):659-66. PubMed ID: 19581876
[TBL] [Abstract][Full Text] [Related]
76. Nonlinear blending: a useful general concept for the assessment of combination drug synergy.
Peterson JJ; Novick SJ
J Recept Signal Transduct Res; 2007; 27(2-3):125-46. PubMed ID: 17613725
[TBL] [Abstract][Full Text] [Related]
77. A review of synergy concepts of nonlinear blending and dose-reduction profiles.
Peterson JJ
Front Biosci (Schol Ed); 2010 Jan; 2(2):483-503. PubMed ID: 20036963
[TBL] [Abstract][Full Text] [Related]
78. Amphipathic Small Molecule AZT Compound Displays Potent Inhibitory Effects in Cancer Cell Proliferation.
Gunasekaran P; Han HJ; Choi JH; Ryu EK; Park NY; Bang G; La YK; Park S; Hwang K; Kim HN; Kim MH; Jeon YH; Soung NK; Bang JK
Pharmaceutics; 2021 Dec; 13(12):. PubMed ID: 34959352
[TBL] [Abstract][Full Text] [Related]
79. The misuse of analysis of variance to detect synergy in combination drug studies.
Caudle RM; Williams GM
Pain; 1993 Dec; 55(3):313-317. PubMed ID: 8121692
[TBL] [Abstract][Full Text] [Related]
80. Dynamical Synergy of Drug Combinations during Cancer Chemotherapy.
Castorina P; Martorana E; Forte S
J Pers Med; 2022 Nov; 12(11):. PubMed ID: 36579581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
